Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Eli Lilly
 More »

  • Biotechs Need to Walk the Walk on Drug Value
    ... Another precompetitive effort, DILI-sim Initiative, joins the Hamner Institutes for Health Sciences with 12 drug developers-Amgen, AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, ...
    5-15-2013
  • Lilly Halts Development of Lymphoma Drug After Phase III Failure
    Eli Lilly said today it is halting development of enzastaurin (LY317615 HCl) after it failed the Phase III PRELUDE study, which assessed the drug candidate as a monotherapy in the ...
    5-10-2013
  • Amgen Forms Joint Venture to Sell Vectibix in China
    that Vectibix was at least as effective as rival drug Erbitux (cetuximab), marketed by Eli Lilly and Merck Serono, as a single agent for mCRC patients with wild-type KRAS tumors. ...
    5-10-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Specific drugs and cancer indications not disclosed. Financial terms not disclosed. Qiagen and Eli Lilly Agreement announced February 13 "Master collaboration" entailing ...
    5-9-2013
  • Pharma Builds Bridges with Advocacy Groups
    ... At Eli Lilly, a company-initiated "community conversation" uniting local leaders and people with severe, persistent mental illness resulted in improved access to psychiatric ...
    5-7-2013
  • Another Alzheimer's Drug Fails Phase III Trial
    ... Gammagard joins a growing number of Alzheimer's drug candidates in failing pivotal-stage clinical trials despite much optimism last year . Last year, Eli Lilly endured two Phase ...
    5-7-2013
  • BMS Partners Again with Ambrx, in Up-to-$112M-and-Up ADC Collaboration
    The others include Astellas, Merck & Co., Eli Lilly, and several undisclosed partners. Companies will join to develop antibody drug conjugates for unspecified cancer indications ...
    5-3-2013
  • GEN | Biolinks
    ... EFEX Eisai Elan Elchrom Scientific Elevation Pharmaceuticals Eleven Biotherapeutics Eli Lilly and Company EMD Millipore Empire State Development Endo Pharmaceuticals Enterprise ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    ... Another precompetitive effort, DILI-sim Initiative, joins the Hamner Institutes for Health Sciences with 12 drug developers-Amgen, AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    ... 14 to develop a biosimilar to the generic version of insulin analog Humalog (Eli Lilly) Glargine: Biocon and Mylan on February 14 announced a strategic collaboration to ...
    4-22-2013
  • Alzheimer's: Lilly Investment Signals R&D Shift
    Eli Lilly signaled today it remains committed to fighting Alzheimer's disease despite two Phase III failures last year through its acquisition from Siemens Medical Solutions USA of ...
    4-17-2013
  • Exploring GPCRs as Therapeutic Targets
    ... disorders at Eli Lilly. "Allosteric regulation of GPCRs has taken the science to a new level of possibilities, although with inherently increased complexity in execution." ...
    4-15-2013
  • CEO Perks
    ... Base compensation, CHF 2,025 million ($2.175 million) John C. Lechleiter, Ph.D. Eli Lilly & Co., chairman, president, and CEO Perks and "all other" compensation: $90,000, ...
    4-12-2013
  • Axe Falls on 1,000 at Lilly
    Eli Lilly said late yesterday it will lay off fewer than 1,000 U.S. sales representatives between now and July 1, in anticipation of steep revenue losses expected as two ...
    4-12-2013
  • Astellas, Ambrx Launch Up-To-$300M ADC Partnership
    Astellas and Merck have joined Bristol-Myers Squibb, Eli Lilly, and several undisclosed companies that have launched collaborations with Ambrx to use its technology in developing ...
    4-5-2013
  • More »

    Journal Articles

  • Two-Year Efficacy and Safety of AIR Inhaled Insulin in Patients...
    Satish K. Garg, Chantal Mathieu, Nadeem Rais, Haitao Gao, Janet A. Tobian, Jeffrey R. Gates, Jeffrey A. Ferguson, David M. Webb, Pierre-Yves Berclaz
    Diabetes Technology & Therapeutics
    Abstract Background: Patients with type 1 diabetes require intensive insulin therapy for optimal glycemic control. AIR® inhaled insulin (system from Eli Lilly and Company, ...
  • Study on the Dosing Accuracy of Commonly Used Disposable Insulin...
    Meike Krzywon, Thomas van der Burg, Uwe Fuhr, Manfred Schubert-Zsilavecz, Mona Abdel-Tawab
    Diabetes Technology & Therapeutics
    A/S, Bagsværd, Denmark], Next Generation FlexPen [Novo Nordisk], and KwikPen(tm) [Eli Lilly, Indianapolis, IN]) were used to deliver 5-unit (low), 30-unit (middle), and 60-unit ...
  • Self-Injection of Insulin Using Appropriate Supportive Devices...
    Kiyomi Masuda, Kazutaka Aoki, Kaori Kikuchi, Uru Nezu, Tomonori Muraoka, Kazuaki Shinoda, Akinobu Nakamura, Makoto Shibuya, Mayumi Takahashi, Mari Kimura, Yasuo Terauchi
    Diabetes Technology & Therapeutics
    In three cases, we used a commercially available self-injection device (HumaHelper(tm); Eli Lilly Japan K.K., Kobe, Japan) to enable self-injection; in the fourth case, we used a ...
  • AIR Insulin Capsules of Different Dose Strengths May Be Combined...
    Amparo de la Peña, Mary Seger, Klaus Rave, Lutz Heinemann, Bernard Silverman, Douglas B. Muchmore
    Diabetes Technology & Therapeutics
    this study examined the exposure and GD effect of doses of AIR® inhaled insulin (Eli Lilly and Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes, Inc., ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll